Donald McCaffrey is Co-Founder, President, & CEO of Resverlogix Corp. He has over 30 years of experience in drug discovery & development, and international conference and tradeshow management across multiple industries, including biotechnology. Don has led Resverlogix through significant change and achievement from its initial days as a private company to becoming a TSX listed company, including raising over $185 million.  In addition to garnering appropriate financing for Resverlogix’s aggressive development plan, Don has strategically directed the Company in its discussions with top global pharmaceutical companies, while creating new therapeutic markets for its key technology platforms. Don’s expertise in corporate operations has attracted an international team of R&D experts to Resverlogix.  This scientific and operational expertise has pioneered RVX-208, a drug which has the potential to be first in a new class of drugs for the treatment of cardiovascular disease.  Under his guidance Resverlogix has won multiple awards including the 2008 WEF Technology Pioneer award.

Don’s career accomplishments have been recognized by the business community and peers, as he was nominated for Ernst & Young Entrepreneur of the Year twice. He is a contributor to community non-profit organizations including the United Way, Mount Royal College, Alberta Children's Hospital, Education Matters, and Calgary Urban Project Society Literacy Program.

Dr. Wong's research interest focus is on the molecular actions of hormones related to the regulation of lipoprotein expression and pathogenesis of diabetes mellitus. His clinical interest encompasses patients with thyroid disease or diabetes mellitus. His most recent successes have come from elucidating the potential therapeutic opportunities for cardiovascular disease by harnessing the regulation of Apolipoprotein A-I (ApoA-I) gene expression.

Dr. Wong keeps active in the academic community with speaking engagements at national and international medical conferences. He has been the author and co-author of more than 275 articles and abstracts and has been invited to sit on more than 40 national or international panels and committees. He has also acted as a consultant to several leading pharmaceutical companies, including Eli Lilly, Merck Frost, GlaxoSmithKline, Solvay Pharmaceuticals and Abbott Laboratories.

Brad has more than 14 years of financial and business experience. Prior to joining Resverlogix, Brad was Executive Vice President and Chief Financial Officer of Royal Host Real Estate Investment Trust, a diversified hospitality trust engaged in hotel ownership, investment, management and franchising, and Canada's second largest hotel REIT. Brad joined Royal Host in January 2004 and held a number of senior positions and was appointed Chief Financial Officer in May 2007 and Executive Vice President in January 2008. Brad's responsibilities included financial reporting, accounting, taxation, investor relations, payroll, information technology and internal audit. As acting Co-Chief Executive Officer of Royal Host, Brad shared responsibility for developing the strategic initiatives of the Trust and leading its executive team in day-to-day operations, as well as investing, financing and real estate transactions. 

Prior to joining Royal Host, Brad was a business consultant and held senior management positions with several companies including Chief Financial Officer of a sulphur export development company and Chief Financial Officer of an oilfield waste water treatment company. Prior thereto, Brad held various positions with a chartered accounting firm.

Brad is a Chartered Accountant and a Chartered Business Valuator, and holds a Bachelor of Commerce from the University of Saskatchewan.

Dr. Johansson has had a distinguished 30 plus year career of which the past 18 years have been in small biotechnology and large pharmaceutical companies with expertise in the cardiovascular disease therapeutic area. He has served as Chief Medical Officer at Nuvelo, Inc., VP, Clinical Research and Development at Lipid Sciences, Inc. and was Co-founder, VP, Clinical Affairs and Senior Clinical Research Fellow of Esperion Therapeutics, Inc. From 1995 to 1997, Dr. Johansson was a medical adviser with executive responsibilities at Pharmacia bringing one lipid lowering product to the market and heading the apolipoproteinA-IMilano clinical program.

Dr. Johansson earned his M.D. and Ph.D. at the Karolinska Institute in Sweden where he lead a successful career as a tenured associate professor at the Karolinska Hospital and as a practicing physician. He has published more than 50 peer-review medical articles, and is a member of several scientific organizations including the American Heart Association and the European Atherosclerosis Society.

Ken has over 25 years experience in the innovative pharmaceutical industry with leading global companies such as Bristol-Myers Squibb, Hoechst Marion Roussel and Marion Merrell Dow. He held a variety of management positions with these companies in the areas of sales and business development, regulatory affairs, reimbursement and market access. Ken's past contributions in helping build leading global cardiovascular brands such as Plavix, Pravachol, Cardizem, and Avapro will provide strategic guidance for the company's technologies in the areas of market analysis, regulatory affairs, pharmacoeconomics, licensing and commercial development.

Dr. Wagner has over 30 years of broad and successful experience in early drug and pharmaceutical development. He has worked with leading biotech and pharmaceutical companies such as Kosan Biosciences, Sugen (a subsidiary of Pharmacia), and Rigel Inc.  His expertise is focused on toxicology, drug metabolism, pharmacokinetics and pharmacology. Dr. Wagner has been a leading force in the early preclinical preparation and development of several important new drug programs such as Sutent, Pfizer’s cancer drug. He will lead Resverlogix’s efforts in establishing overall management of the preclinical programs to support development of compounds for IND candidates.

Over the past 20 years Allan has built up a successful career as a Research and Development professional in cardiology. With his expertise and understanding of the market place, he is able to uniquely motivate teams of scientists on both the levels of discovery and applicability. Prior to joining Resverlogix, Allan was the CEO for Nile Therapeutics, an early stage bio-pharmaceutical in cardiovascular science, particularly in acute heart failure. Moreover, Allan led the international development program for Natrecor at Scios Inc., a Johnson & Johnson company. In addition to this work in the United States, Allan has worked with several large pharmaceutical companies in leading positions on the clinical development programs for cardiovascular disease including Astra-Zeneca, Bristol-Myers Squibb and Novartis.

Allan received his M.D. and Ph.D. from the Karolinska Institute in Sweden where he initially worked in a number of hospital settings, followed by his position as an Associate Professor in Cardiology at the Karolinska Institute. He has published approximately 50 articles and abstracts.

Dr. Peter R. Young is Senior Vice President of Discovery Research at Resverlogix. Peter comes to Resverlogix with many years of experience in the pharmaceutical industry with a strong and proven background discovering and validating targets, and advancing drug discovery programs and product candidates which have reached the clinic.

Prior to Resverlogix, Peter was Vice President of Research at Affymax where he supported the development of Hematide/peginesatide, a potential once a month treatment for anemia. Earlier management positions included VP of Biology at Genelabs, VP of Biology at Celera and VP of Research at SUGEN. In these positions, Peter was responsible for driving the discovery and early development of potential drugs for autoimmune, cardiovascular, cancer and hepatitis C indications, several of which are currently being tested in the clinic. Earlier in his career while working for Dupont Pharmaceuticals (now BristolMyers Squibb) and SmithKline Beecham (now GSK), he led therapeutic programs in metabolic, autoimmune and hematological diseases including the discovery of eltrombopag, which is currently marketed as Promacta by GSK for the treatment of idiopathic thrombocytopenia purpura, and p38 MAP kinase, a novel therapeutic target that yielded several clinical candidates for the treatment of rheumatoid arthritis.

Peter earned his Ph.D. from the University of Pennsylvania. He has published more than 100 articles and reviews, is a reviewer for several journals and is listed as an inventor on more than 30 issued patents.

Ms. Tina M. Rarick joined Resverlogix as VP of Business Operations and Program Management. She leads Business Operations, Regulatory Affairs, Quality Assurance and Program Management. Tina has nineteen years of combined experience working in diverse corporate cultures from start-ups to multinationals. At Resverlogix Ms. Rarick uses her extensive pharmaceutical business and strategy expertise to lead global development and align milestone driven corporate objectives for the CEO and Board of Directors. Prior to joining Resverlogix, Tina worked in various management positions at Roche Pharmaceuticals, Schering-Plough, Pharmacia and SUGEN. Ms. Rarick received her B.S. in Biology with a minor in Chemistry from the University of Utah and her MBA from Duke University. She also served on the faculty at the University of California, San Francisco where she has lectured on drug development strategy.

Henrik C. Hansen joined Resverlogix in 2005 and currently holds the position of VP of Pharmaceutical Development. Henrik is responsible for the development and implementation of comprehensive manufacturing strategies for drug substances and drug products, as well as assuming oversight of the intellectual property portfolio. Henrik has more than 13 years of experience, from both academia and industry, in basic research, drug discovery, and drug development. His areas of expertise include medicinal chemistry and carbohydrate chemistry, process development, and manufacturing of drug substances and drug products under cGMP for clinical use.

Henrik holds a M.Sc. in Chemical Engineering from the Technical University of Denmark and a Ph.D. in Organic Chemistry from Lund University, Sweden. He has authored or co-authored more than 40 articles and meeting abstracts and is listed as inventor of 9 patent families.